Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care?

EuroIntervention 2021;17:362-363. DOI: 10.4244/EIJV17I5A63

Marco Valgimigli
Marco Valgimigli1,2, MD, PhD; Antonio Landi1, MD
1. Division of Cardiology, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; 2. Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland
The oral P2Y12 inhibitors prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI); however, they are associated with high residual platelet reactivity (HRPR) up to 4-6 hours after loading1. On-treatment HRPR correlates with procedural success, myocardial damage and clinical outcomes. Hence, more rapid antiplatelet agents remain desirable in STEMI. Cangrelor is an intravenous (IV) P2Y12 inhibitor with a rapid and reversible antiplatelet effect, though it prompts a lower inhibition of platelet aggregation (IPA) at light transmittance aggregometry (LTA) than tirofiban, an intravenous glycoprotein IIb/IIIa inhibitor (GPI)2. Moreover, cangrelor ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
How Stoic principles can help when performing complex interventions

Latest news